

Alaska Medicaid  
**MAT Provider Standards of Care Attestation**

Fax this form to: 1-888-603-7696 Questions: Call Magellan Medicaid Administration at 800-331-4475

Or mail this request to: Medicaid PA Unit, 14100 Magellan Plaza, Maryland Heights, MO 63043

---

**Application Process:**

Prescribers of office-based opioid treatment wishing to demonstrate compliance with Alaska Medicaid standards of care may complete and submit the Provider Attestation and Application for review to Magellan Medicaid Administration (see fax information above). Contact Magellan to start the review process and submit any additional required documents to Magellan. Magellan will inform you if you meet the requirements set forth in these criteria to be enrolled or credentialed as a Medicaid provider in their network. Attesting to meeting Alaska Medicaid standards of care criteria does not guarantee approval of the application.

**Checklist:**

- Physicians, Nurse Practitioners, Physician Assistants: completion of required training course hours.
- DEA DATA 2000 waiver registration in good standing.
- Description of the roles and functions of the members of the prescriber's interprofessional team. Team members are not required to be co-located with the prescriber, but the prescriber must outline how she or he will ensure coordination with an individual's care team.
- Description of how the prescriber provides or ensures interdisciplinary care coordination for patients.
- Description of how treatment for comorbid conditions (physical or mental health conditions) is provided as needed on-site or through collaboration with other providers, including recovery support.
- Outline of network supports that are employed to ensure patients needing a higher level of care are appropriately referred.
- Adherence to criteria outlined in Appendix.
- Compliance with all state and federal laws.

Prescribers shall provide clinic protocol documents to demonstrate congruency with standards of practice.







Alaska Medicaid  
**MAT Provider Standards of Care Attestation**

Fax this form to: 1-888-603-7696 Questions: Call Magellan Medicaid Administration at 800-331-4475  
 Or mail this request to: Medicaid PA Unit, 14100 Magellan Plaza, Maryland Heights, MO 63043

**Appendix: Buprenorphine-based Medication Assisted Therapy Office-Based Opioid Treatment**

Opioid dependency treatment and pathways to recovery demonstrate the highest persistence of opioid misuse avoidance when comprehensive treatment strategies are available to individuals. Integration of counseling and behavioral health treatment with opioid partial agonists is evidence-based and required under federal law. For individuals who opt for treatment with buprenorphine-based medication assisted therapy, (1) accessibility, (2) comprehensiveness, (3) coordination, and (4) continuity are critical components.

ACCESSIBILITY	COMPREHENSIVENESS	COORDINATION	CONTINUITY
<ul style="list-style-type: none"> <li>• Patient-centric MAT options</li> <li>• Management of barriers to treatment</li> <li>• Initial and follow-up care available</li> </ul>	<ul style="list-style-type: none"> <li>• MAT</li> <li>• Integration of behavioral health services</li> <li>• HIV/Hep C screening and treatment</li> <li>• Family-planning options</li> <li>• Prenatal care</li> <li>• Co-morbid conditions</li> <li>• Family engagement</li> <li>• Education</li> <li>• Harm reduction, self-care</li> </ul>	<ul style="list-style-type: none"> <li>• Primary care, other care providers</li> <li>• Specialty or other service referral prn</li> <li>• Level of care escalation referral prn</li> <li>• Connection with social supports, e.g., housing, education, etc.</li> <li>• Peri-procedure treatment planning coordination</li> </ul>	<ul style="list-style-type: none"> <li>• Patient-centric treatment plan1, including care management</li> <li>• Team emphasis</li> <li>• Exit/re-entry protocols</li> </ul>

Drug Enforcement Agency (DEA) Drug Addiction Treatment Act (DATA) 2000 waived prescribers opting to prescribe buprenorphine-based medication assisted treatment for Medicaid members shall conform to the minimum standards of care outlined in this document. Prescribers may demonstrate conformation with these standards of care either by (1) presenting prior authorization requests for each individual member being prescribed buprenorphine-based products beyond the first 28 days of therapy or (2) satisfactorily completing the above attestation form and committing to at least the minimum standards of care throughout the authorized period. Prescriptions filled during the prescriber’s 12-month authorization period will not require separate individual prior authorizations. Prescribers who fail to maintain conformation with the minimum standards of care outlined in this document will be required to present prior authorization requests for individual members until such time as the prescriber is able to resolve any relevant deficiencies.

**PREFERRED MEDICATION:**

Refer to Preferred Drug List available at: <http://dhss.alaska.gov/dhcs/pages/pharmacy/medpriorauthoriz.aspx>

**INDICATION:**

Opioid dependence in individuals at least 16 years old

**CRITERIA FOR APPROVAL:**

Patients new to buprenorphine-based medication assisted therapy (MAT) within the most recent 60 days will not require prior authorization when initiating therapy. To ensure prescribers are adhering to best-practice principles, prescribers must seek prior authorization for continuation of therapy and ensure the following criteria are met:

1. The prescriber attests to maintaining authorization to prescribe buprenorphine treatment for opioid dependency, meets all qualifications (State and Federal; e.g., DATA-certified), has been issued a special identification number from the Drug Enforcement Administration, and may not accept cash payments from Medicaid members; **AND**
2. The patient is not receiving other narcotic analgesics, stimulants, carisoprodol, benzodiazepines, or tranquilizers, and is not consuming alcohol while receiving MAT; **AND**
3. Patient and prescriber have a defined MAT treatment plan (including functional goals) and projected timeline on record; **AND**
4. Patient is receiving regular psychosocial support; **AND**
5. Maximum dose of buprenorphine less than or equal to:

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (Via return FAX) immediately and arrange for the return or destruction of these documents



## MAT Provider Standards of Care Attestation

Fax this form to: 1-888-603-7696 Questions: Call Magellan Medicaid Administration at 800-331-4475

Or mail this request to: Medicaid PA Unit, 14100 Magellan Plaza, Maryland Heights, MO 63043

- Buprenorphine (Suboxone, Subutex) – 24mg/day
  - Buprenorphine (Bunavail) – 12.6mg/day (two 6.3mg films)
  - Buprenorphine (Zubsolv) – 22.8mg/day (two 11.4mg tablets)
6. Single ingredient oral buprenorphine products (e.g., Subutex) are restricted to pregnant females.

### PRESCRIBER RESPONSIBILITIES:

1. If buprenorphine prescriber is not providing psychosocial support to the patient, the MAT-prescriber maintains a coordinated shared care plan with another practitioner and maintains copies of the care plan with both practitioners; **AND**
2. Prescribers are responsible for routinely screening patients for anxiety and mental health challenges and providing supportive access to care.
3. If the patient has chronic pain, the prescriber develops a patient-centric defined treatment plan that optimizes non-opioid therapies in order to manage chronic pain in the absence of opioids.
4. Patients are encouraged to enroll in the AMCCI program; prescribers may refer patients.
5. Prescribers are responsible for requesting prior authorization for continuation of therapy in sufficient time to avoid patients not having access to medically necessary treatment.
6. Prescribers are responsible for maintaining an up-to-date treatment plan and reviewing at least every six months with the patient. Trial tapers to lower maintenance doses should be considered when the patient has been stabilized and the patient demonstrates readiness.

### CRITERIA RESULTING IN DENIAL:

1. The patient is 15 years old or younger; **OR**
2. The patient is being treated for anything other than opioid dependence; **OR**
3. The patient has not agreed to adhere to a treatment plan; **OR**
4. The prescriber does not meet all qualifications to prescribe buprenorphine-based products for opioid dependence; **OR**
5. The patient is receiving narcotic analgesics, stimulants, carisoprodol, benzodiazepines, tranquilizers, or is consuming alcohol regularly.

### LENGTH OF AUTHORIZATION:

1. If the prescriber has successfully completed the Standards of Care Attestation application, prescriptions filled during the prescriber's 12-month authorization period will not require separate individual prior authorizations.
2. Until a prescriber has successfully completed the attestation for the Standards of Care, individual patient prior authorization may be authorized for up to six (6) months. After 6 months, a new prior authorization may be obtained.

### DISPENSING LIMIT:

The dispensing limit is a 34-day supply of medication.

### MAXIMUM DAILY DOSE:

Daily doses exceeding the following will not be authorized:

- Buprenorphine (Suboxone, Subutex) – 24mg/day (three 8 mg films)
- Buprenorphine (Bunavail) – 12.6mg/day (two 6.3mg films)
- Buprenorphine (Zubsolv) – 22.8mg/day (two 11.4mg tablets)

Alaska Medicaid  
**MAT Provider Standards of Care Attestation**

Fax this form to: 1-888-603-7696 Questions: Call Magellan Medicaid Administration at 800-331-4475

Or mail this request to: Medicaid PA Unit, 14100 Magellan Plaza, Maryland Heights, MO 63043

---

**REGULATORY AUTHORITY:**

Alaska Medicaid prior authorization clinical criteria for use and standards of care are developed under the authority granted to the Alaska Medicaid Drug Utilization Review Committee in compliance with 7 AAC 120.120, 7 AAC 120.130, 7 AAC 120.140, 42 USC 1396r-8, and 42 CFR 456 Subpart K. The Committee considers each of the following in the development of clinical criteria for use as outlined in 7 AAC 105.230(c): medical necessity, clinical effectiveness, cost-effectiveness, and likelihood of adverse effects as well as service-specific requirements. Drugs which fall into a specific therapeutic category but are approved by the FDA after the most recent revision of that therapeutic drug class review will be subject to the same standards set by DUR Committee for the relevant therapeutic category's prior authorization clinical criteria for use. This includes a requirement to utilize or trial preferred agents prior to the utilization of a non-preferred agent within a given therapeutic category unless a documented clinical contraindication exists. Covered outpatient drugs must meet the parameters defined in 7 AAC 120.110. Drugs which the FDA has approved but clinical benefit has not been established will not be approved.

**REFERENCES:**

1. Alaska Administrative Code. 12 AAC 40.975. Prescribing controlled substances.
2. Mullin D, Martin S. Primary Care of Patients with Opioid Use Disorder (slide presentation). Presented at Alaska Primary Care Association. 2017.
3. U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Buprenorphine Waiver Management, available at <https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver>
4. U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Qualify for Nurse Practitioners (NPs) and Physician Assistants (PAs) Waiver, available at <https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/qualify-np-pa-waivers>
5. U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration, PEP18: Treatment Locator, available at <https://store.samhsa.gov/shin/content//PEP18-TREATMENT-LOC/PEP18-TREATMENT-LOC.pdf>
6. Center for Substance Abuse Treatment. *Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction*. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.

**Confidentiality Notice:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (Via return FAX) immediately and arrange for the return or destruction of these documents

© 2018, Magellan Health Services, Inc. All rights reserved.

**Magellan**  
**HEALTH**<sup>SM</sup>